Anthrax immune globulin, tradename Anthrasil, is a human immune globulin that is used in combination with antibiotics to treat anthrax.[2] It was developed by Cangene and purchased in 2011 by the Biomedical Advanced Research and Development Authority (BARDA) under Project Bioshield. On 24 March 2015 it was granted approval by the United States Food and Drug Administration for use in treating inhalation anthrax in conjunction with antibiotics.[3][4]
| Clinical data | |
|---|---|
| Trade names | Anthrasil |
| Routes of administration | Intravenous |
| Legal status | |
| Legal status | |
| Identifiers | |
| ChemSpider |
|
| UNII | |
Preparation
editAnthrax immune globulin is prepared from the plasma of donors who have been vaccinated against anthrax.[citation needed]
Safety and efficacy testing
editDue to the ethical and feasibility concerns with testing the efficacy of anthrax immune globulin in humans, it was tested in rabbits and monkeys under the FDA's animal efficacy rule. Following efficacy testing, anthrax immune globulin was tested for safety in human volunteers, where the most common side effects were headache, back pain, nausea and infusion site pain and swelling.[citation needed]
References
edit- ^ "Extraordinary use". Health Canada. 9 May 2018. Retrieved 13 April 2024.
- ^ Savransky V, Ionin B, Reece J (May 2020). "Current Status and Trends in Prophylaxis and Management of Anthrax Disease". Pathogens (Basel, Switzerland). 9 (5): 370. doi:10.3390/pathogens9050370. PMC 7281134. PMID 32408493.
- ^ "FDA approves treatment for inhalation anthrax". United States Food and Drug Administration. 25 March 2015.
- ^ "Anthrasil Approval History". Drugs.com. Retrieved 26 March 2015.